Find your way with your package manager, use pip in a virtual environment or use pyenv. Eg. $ git clone https://github.com/noraj/flask-session-cookie-manager.git ...
Commissions do not affect our editors' opinions or evaluations. Biotech stocks are not for the faint of heart. These highly volatile equities can see stomach-churning price swings, driven by how ...
Ministry of Science & Technology, Government of India, has opened applications for its PhD program in Biotechnology for the January 2025 session.
2024 was the year of the private megaround. Nine-figure financings dominated biotech’s venture funding landscape, with 96 such rounds tallied by Endpoints News. The bevy … ...
Carmell acquires Elevai Skincare, adding $2.5M in annual revenue and advanced exosome technology to its portfolio. Deal includes $1.1M in equity, $57K in cash, and earnouts tied to sales and ...
The biotechnology sector once again starts a new year on shaky footing. Acquisitions of publicly traded biotech companies have slowed. An anticipated upswing in initial public offerings hasn’t ...
Local biotech Heron Therapeutics is relocating its headquarters from San Diego to North Carolina, where it says the area’s burgeoning biotech scene “provides ample space for growth and ...
All the news that moves the needle in pharma and biotech Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters. Receive The Pharma ...
Continuously trying to find new ways of treating diabetes, cancer, and autoimmune diseases, the Indian biotech company has developed and commercialized novel biologics, biosimilars, and complex small ...
Krystal Biotech's VYJUVEK, a groundbreaking gene therapy for DEB, achieved $83.8M in Q3 2024 sales, doubling from Q4 2023. Trading at 57x 2024 earnings, Krystal's stock appears expensive but is ...
Lower interest rates boost biotech investments by increasing risk appetite, benefiting pre-commercial biotechs with high cash burn and no revenue. Biotech IPOs show resilience. Recent market ...
If the last few months are any guide, there will be no shortage of surprises and challenges for the biotech industry in the new year. Donald Trump will begin his second term, possibly bringing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback